Wuppertal, Germany

Guillaume Levilain

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 20.0

ph-index = 1


Company Filing History:


Years Active: 2022-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Innovations of Guillaume Levilain

Introduction

Guillaume Levilain is a notable inventor based in Wuppertal, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds for treating various diseases. With a total of two patents to his name, his work focuses on innovative solutions for health-related issues.

Latest Patents

Guillaume Levilain's latest patents include "Substituted S-alaninate derivatives" and "Prodrugs of substituted triazole derivatives and uses thereof." The first patent relates to substituted S-alaninate derivatives and outlines processes for their preparation. It also discusses their application in creating medicaments for treating and preventing vascular disorders, especially thrombotic or thromboembolic complications. The second patent involves prodrugs of specific triazole derivatives, detailing their preparation and use in pharmaceutical compositions aimed at treating renal and cardiovascular diseases.

Career Highlights

Throughout his career, Guillaume has worked with prominent companies such as Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft. His experience in these organizations has allowed him to develop and refine his innovative ideas in the pharmaceutical sector.

Collaborations

Guillaume has collaborated with notable colleagues, including Hartmut Beck and Stefanie Mesch. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Guillaume Levilain's contributions to medicinal chemistry through his patents demonstrate his commitment to innovation in healthcare. His work continues to impact the treatment of critical health conditions, showcasing the importance of research and development in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…